SAN DIEGO, Oct. 5, 2021 /PRNewswire/ -- On October 21th at 9AM PST/ 12PM EST, Dr. Kelly Wosnik, Owner/ NP-C of Bristol Health will share practice patterns and associated clinical implications using pharmacogenomic testing (PGx) to pinpoint the right treatments for mental illnesses. This is especially urgent as we enter the second winter season of COVID-19.
Dr. Wosnik's mental health practice Bristol Health (Orem, Utah) has used PGx testing since its founding in 2015. This webinar will provide her unique perspective on how to improve care with PGx testing in her clinical practice.
At the webinar, Dr. Behnaz Sarrami, PharmD, Medical Science Liaison at AltheaDx, will also speak about the best practices in interpreting PGx tests to help link genes with medications that treat depression and anxiety.
The educational session will cover:
AltheaDx CEO David Nikodem further commented, "Psychiatric nurse practitioners recognize the path to selecting mental health treatment is tough, especially as Seasonal Affective Disorder (SAD) and other winter-time mental health issues can be more acute. Using PGx testing to choose the correct drug treatment regimen is vital to achieving patient stability and wellness, while lowering side effects and medical costs overall."
About AltheaDx:
AltheaDx, Inc. is a commercial stage molecular diagnostics company specializing in the field of pharmacogenomics (PGx). IDgenetix® is AltheaDx's PGx product test for depression and anxiety and is supported by a published/peer-reviewed Randomized Controlled Trial that demonstrated clinical utility over standard of care when physicians used the test prior to prescribing a medication.
For media inquiries contact:
Croom Lawrence
clawrence@altheadx.com
Forward-Looking Statements
This press release contains forward-looking statements including, but not limited to, statements related to AltheaDx's ability to raise awareness for mental health and get patients the help they need, IDgenetix® ability to help patients improve their chances of response and/or remission by identifying the correct medication more efficiently and enable healthcare providers to make timely and evidence-based decisions, and that PGx testing can be a powerful lever in achieving wellness and remission when compared to standard-of-care. These forward-looking statements are based on our current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks that AltheaDx's actual future financial and operating results may differ from its expectations or goals, AltheaDx's ability to commercialize and successfully launch its products, risks relating to AltheaDx's ability to successfully implement its business strategies, including potential competition, the ability to protect intellectual property and defend patents, regulatory obligations and oversight, including any changes in the legal and regulatory environment in which AltheaDx operates, the effects of the COVID-19 pandemic on the business and AltheaDx's efforts to address its impact, subsequent study results and findings that contradict earlier study results and findings, and the IDgenetix® ability to provide the aforementioned benefits among others. We undertake no duty or obligation to update any forward-looking statements contained in this press release as a result of new information.
SOURCE AltheaDx
